학술논문
Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease.
Document Type
Article
Author
Arena, Giuseppe; Landoulsi, Zied; Grossmann, Dajana; Payne, Thomas; Vitali, Armelle; Delcambre, Sylvie; Baron, Alexandre; Antony, Paul; Boussaad, Ibrahim; Bobbili, Dheeraj Reddy; Sreelatha, Ashwin Ashok Kumar; Pavelka, Lukas; J Diederich, Nico; Klein, Christine; Seibler, Philip; Glaab, Enrico; Foltynie, Thomas; Bandmann, Oliver; Sharma, Manu; Krüger, Rejko
Source
Subject
*PARKINSON'S disease
*DELAYED onset of disease
*MITOCHONDRIA
*FALSE discovery rate
*URSODEOXYCHOLIC acid
*OXIDATIVE phosphorylation
*
*
*
*
*
Language
ISSN
0364-5134
Abstract
Objective: The aim of our study is to better understand the genetic architecture and pathological mechanisms underlying neurodegeneration in idiopathic Parkinson's disease (iPD). We hypothesized that a fraction of iPD patients may harbor a combination of common variants in nuclear‐encoded mitochondrial genes ultimately resulting in neurodegeneration. Methods: We used mitochondria‐specific polygenic risk scores (mitoPRSs) and created pathway‐specific mitoPRSs using genotype data from different iPD case–control datasets worldwide, including the Luxembourg Parkinson's Study (412 iPD patients and 576 healthy controls) and COURAGE‐PD cohorts (7,270 iPD cases and 6,819 healthy controls). Cellular models from individuals stratified according to the most significant mitoPRS were subsequently used to characterize different aspects of mitochondrial function. Results: Common variants in genes regulating Oxidative Phosphorylation (OXPHOS‐PRS) were significantly associated with a higher PD risk in independent cohorts (Luxembourg Parkinson's Study odds ratio, OR = 1.31[1.14–1.50], p‐value = 5.4e‐04; COURAGE‐PD OR = 1.23[1.18–1.27], p‐value = 1.5e‐29). Functional analyses in fibroblasts and induced pluripotent stem cells‐derived neuronal progenitors revealed significant differences in mitochondrial respiration between iPD patients with high or low OXPHOS‐PRS (p‐values < 0.05). Clinically, iPD patients with high OXPHOS‐PRS have a significantly earlier age at disease onset compared to low‐risk patients (false discovery rate [FDR]‐adj p‐value = 0.015), similar to prototypic monogenic forms of PD. Finally, iPD patients with high OXPHOS‐PRS responded more effectively to treatment with mitochondrially active ursodeoxycholic acid. Interpretation: OXPHOS‐PRS may provide a precision medicine tool to stratify iPD patients into a pathogenic subgroup genetically defined by specific mitochondrial impairment, making these individuals eligible for future intelligent clinical trial designs. ANN NEUROL 2024;96:133–149 [ABSTRACT FROM AUTHOR]